Impact of Text Messages to Promote Secondary Prevention After Acute Coronary Syndrome (IMPACS)
Impact of a Mobile Phone Text Messages Intervention on the Secondary Prevention of Cardiovascular Events After Acute Coronary Syndrome
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Purpose of the trial: The purpose of the study is to evaluate the effectiveness of automated mobile phone text message-based intervention for secondary prevention after acute coronary syndrome hospitalization.
Trial design: Two-parallel arm, single-blind, block randomization.
Primary endpoint: The proportion achieving guideline levels of modifiable risk factors (LDL-C <70mg/dL, blood pressure <140/90 mm Hg, exercising regularly [≥5 d/wk × 30minutes of moderate exercise per session], nonsmoker status, and BMI <25). The investigators prespecified in the statistical analysis plan the efficacy variable of proportion achieving combined risk factor control (achieving risk factor targets in 4 or more of the 5 modifiable risk factors listed above) as a measure of a multiple risk factor effect.
Secondary endpoints: The plasma LDL-C level at 6 months, Level of physical activity, Blood Pressure, Medication adherence measured via Morisky scale, Proportion of non-smokers, Body mass index (BMI), Rates death and hospitalization up to 6 months.
Duration of follow-up: 6 months
Trial treatment:
Intervention: The treatment group will receive the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the text-messaging intervention. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living habits texts. There will be four streams: one for patients who are non-smokers and are free of diabetes; one for current/recent smokers; one for diabetic patients; and one for smoker and diabetic patients. Texts will be sent out 4 times per week for 180 days. All participants in the same stream will receive the same texts in the same order.
Control: The usual care group will receive standard discharge treatment, instructions, and information for patients with acute coronary syndrome. The participants will also receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
Expected sample size, enrollment and expected number of centers:
Sample size = 160 Recruitment start date: November, 2017 Recruitment end date: May, 2019 Follow-up end date: November, 2019 Number of centers: 1
Statistical considerations:
- Intention to treat analysis
- The trial has >90% power (2 sided alpha = 0.05) to detect 15% difference in achieving risk factor targets in 4 or more of the 5 modifiable risk factors listed.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
MG
-
Belo Horizonte, MG, Brésil, 30575210
- Recrutement
- Luiz Guilherme Passaglia
-
Contact:
- Luiz G Passaglia, master's
- Numéro de téléphone: 3199038674
- E-mail: lg.passaglia@uol.com.br
-
Chercheur principal:
- Luiz G Passaglia, M.D.
-
Chercheur principal:
- Antônio LP Ribeiro, M.D., Ph.D
-
Sous-enquêteur:
- Luisa CC Brant, M.D., Ph.D
-
Sous-enquêteur:
- Bruno R Nascimento, M.D., Ph.D.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Consecutive patients who have been hospitalized at the UFMG's University Hospital with primary or secondary diagnosis of Acute Coronary Syndrome and are discharged for outpatient follow-up;
- Age ≥ 18 years, of both sexes;
- Patients who are able to receive text messages by their own mobile phone.
Exclusion Criteria:
- Refusal or inability to sign the Informed Consent.
- Complete illiteracy.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Experimental
Automated semi-personalized mobile phone text message-based intervention for secondary prevention plus usual care.
|
The treatment group will receive the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the text-messaging intervention.
The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living habits texts.
There will be four streams: one for patients who are non-smokers and are free of diabetes; one for current/recent smokers; one for diabetic patients; and one for smoker and diabetic patients.
Texts will be sent out 4 times per week for 180 days.
All participants in the same stream will receive the same texts in the same order.
The usual care group will receive standard discharge treatment, instructions, and information for patients with acute coronary syndrome.
They will also receive simple and short text messages related to the importance of trial participation.
|
|
Aucune intervention: No Intervention
Usual Care
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Escore of combined risk factor control
Délai: 6 months
|
The proportion achieving guideline levels of modifiable risk factors (LDL-C <77mg/dL, blood pressure <140/90 mm Hg, exercising regularly [≥5 d/wk × 30minutes of moderate exercise per session], nonsmoker status, and BMI <25).
We prespecified in the statistical analysis plan the efficacy variable of proportion achieving combined risk factor control (achieving risk factor targets in 4 or more of the 5 modifiable risk factors listed above) as a measure of a multiple risk factor effect
|
6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Plasma LDL-C level
Délai: 6 months
|
Fasting blood sample
|
6 months
|
|
Level of physical activity (measured via
Délai: 6 months
|
Measured by research blinded to treatment allocation - The level of physical activity will be mensured by the International Physical Activity Questionnaire Short Form (IPAQ-SF) and it will be validated in one-fifth of the participants by using accelerometers
|
6 months
|
|
Blood Pressure
Délai: 6 months
|
Measured by research blinded to treatment allocation - 3 resting, sitting digital recordings, mean of last 2 readings
|
6 months
|
|
Proportion of non-smokers
Délai: 6 months
|
Measured by research blinded to treatment allocation - Self-reported smoking / quitting attempts will be confirmed with a Carbon Monoxide Meter Breath Test
|
6 months
|
|
Body mass index (BMI)
Délai: 6 months
|
Measured by research blinded to treatment allocation
|
6 months
|
|
Medication adherence (measured via "Medida de adesão aos tratamentos" - MAT)
Délai: 6 months
|
Measured by research blinded to treatment allocation It is an instrument composed of seven items that evaluate the behavior of the individual in relation to daily use of medicines.
The answers are obtained by means of a six-point ordinal scale that varies from always (1) to never (6).
The values obtained with the answers to the seven items are summed and divided by the number of items (values vary from 1 to 6).
Subsequently, values 5 and 6 are computed as one (adherent) and the others are computed as zero (non-adherent).
|
6 months
|
|
Death from any cause
Délai: 6 months
|
Medical records and database
|
6 months
|
|
Rehospitalization
Délai: 6 months
|
Self-report, medical records and database
|
6 months
|
|
Cardiovascular death
Délai: 6 months
|
Medical records and database
|
6 months
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CEP1.883.227
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .